Optimal CAB Case Study: Pediatric Dolutegravir
A framework to support new product introduction in national health systems
Resource Library


- May 16
CAB Case Studies from Ethiopia

- Feb 27
Community Statements on DRV/r Use in 2L

- Feb 16
CAB Case Studies from Tanzania

- Feb 16
CAB Case Studies from Zambia

- Feb 16
CAB Case Studies from Nigeria

- Feb 16
CAB Case Studies from Uganda

- Oct 18, 2022
Prevention Product Preference Brief

- Oct 18, 2022
CAB-LA Community Meeting Overview

- Sep 12, 2022
AHD Community Advocacy Video

- Sep 12, 2022
Pediatric DTG Advocacy Video for Communities (English and French)

- Jul 31, 2022
Optimal CAB Case Study: Enabling and Ensuring Equitable HIV Treatment for Women

- Jul 31, 2022
Case Study: Community-Developed HIV Care and Treatment Literacy Improves Uptake of Optimal Medicines

- Jun 16, 2022
AHD Social Media Campaign

- Oct 18, 2021
The Community's Corner: Optimal CAB Newsletter


- Jul 9, 2021
Community Resources for Pediatric DTG Scale-Up

- Aug 1, 2020
AfroCAB / CHAI Community Consultation and Webinar Series

- Mar 1, 2020
Communique of the Kigali Community Meeting on Dolutegravir and Weight Gain

- Dec 1, 2018
Case Study: Partnering with Communities of PLHIV Accelerates Access to Optimal Treatment

- Nov 1, 2017
Optimal ARV Community Advisory Board Terms of Reference